PSIQI

Research notes · Reviewed November 22, 2026

Evidence before
expectation.

The developments behind the thesis, with their status and practical limits kept in view.

FDA guidance

July 2026 · Final guidance

FDA finalized its psychedelic clinical-investigation guidance, replacing the 2023 draft.

Clinical-development guidance is a sector milestone, not permission for PSIQI to operate.

Read the source for FDA guidance

Clinical development

November 9, 2026 · Company announcement

Compass Pathways reported completing its COMP360 new drug application submission.

Submission is distinct from approval. Compass is not represented as a PSIQI customer or partner.

Read the source for Clinical development

Research supply

January 5, 2026 · Established quotas

DEA established 2026 national quotas of 50,000 g for psilocybin and 80,000 g for psilocyn.

These are national quantities, not market revenue, actual production or an allocation to PSIQI.

Read the source for Research supply

Forward indicator

November 10, 2026 · Proposal

The proposed 2027 quotas include 60,000 g of psilocybin and 93,600 g of psilocyn.

The cited quantities are proposed. They must not be presented as finalized authorization.

Read the source for Forward indicator

Operating structure

Colorado · Rules 7010 and 7015

Testing independence, licensing and certification shape the potential operating model.

The effective rules and ownership structure require transaction-specific review.

Read the source for Operating structure

Acquisition diligence

Federal · 21 CFR 1301.52

DEA registrations do not automatically transfer with a laboratory acquisition.

The transaction must account for required consent and operating permissions.

Read the source for Acquisition diligence

Manufacturing quality

FDA · ICH Q7

API manufacture requires an appropriate system for managing quality.

Manufacturing is a separate capability decision from analytical testing.

Read the source for Manufacturing quality

Existing competition

Cayman Chemical · Service description

Established suppliers advertise reference standards and scientific services.

PSIQI needs a demonstrated customer advantage in an existing competitive market.

Read the source for Existing competition

Partner landscape

Psygen · Service description

Specialist providers advertise psychedelic API development and manufacturing.

Partnership should be evaluated alongside the economics of owned manufacturing.

Read the source for Partner landscape

How to read these notes

Context is not a forecast.

Regulatory developments and company milestones help frame the opportunity. They do not demonstrate demand for PSIQI, establish a market size, or substitute for acquisition diligence.

Supplier descriptions are first-party statements. No organization cited here is represented as a PSIQI customer, partner or endorser. Legal requirements must be checked against the effective rules for the proposed activity and transaction.

Build the foundation with us

Good science starts
with a conversation.

For investors, laboratory owners and scientific partners.

info@psiqi.com